Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
- Published In:
- Diabetes care, 40(5), 647-654 (2017)
- Authors:
- Nauck, Michael A(8), Frossard, Jean-Louis, Barkin, Jamie S, Anglin, Greg, Hensley, Ingrid E, Harper, Kristine D, Milicevic, Zvonko
- Database ID:
- RPEP-03413
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03413APA
Nauck, Michael A; Frossard, Jean-Louis; Barkin, Jamie S; Anglin, Greg; Hensley, Ingrid E; Harper, Kristine D; Milicevic, Zvonko. (2017). Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.. Diabetes care, 40(5), 647-654. https://doi.org/10.2337/dc16-0984
MLA
Nauck, Michael A, et al. "Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.." Diabetes care, 2017. https://doi.org/10.2337/dc16-0984
RethinkPeptides
RethinkPeptides Research Database. "Assessment of Pancreas Safety in the Development Program of ..." RPEP-03413. Retrieved from https://rethinkpeptides.com/research/nauck-2017-assessment-of-pancreas-safety
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.